Overview
Initial Therapy Matters for Clostridioides difficile – Get it Right the First Time
C. difficile Clinical Commentary
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Never miss a diagnosis of Clostridioides difficile (C. difficile) infection again! This engaging activity features a dive into the diagnosis and treatment of community-acquired C. difficile infection with a multidisciplinary expert panel in a roundtable discussion. In this one-of-a-kind educational experience, a captivating moderator leads a team of 3 physicians from internal medicine, infectious disease, and gastroenterology to provide clinical commentary on the latest guidelines and best practices in the management of patients with primary and recurrent episodes of C. difficile infection. As a bonus, after completing the activity, learners can access an infographic (educational resource) to help integrate the content presented into their daily practice and improve the recognition of C. difficile infection among internists.
This activity is intended for physicians with a target audience of internal medicine physicians and other clinicians who care for patients at risk of serious C. difficile infection.
Although C. difficile infection has historically been considered a hospital-acquired infection, it is now common in the community settings. Therefore, internal medicine physicians and primary care providers need to be well-versed not only in the diagnosis, but also in the selection of therapy for C. difficile infection. To reduce severe or recurrent C. difficile infection, and C. difficile-associated hospitalizations, physicians must promptly recognize the signs and symptoms of C. difficile infection, identify patients at high risk for recurrence, and select the most appropriate therapy while working collaboratively with specialists to improve patient outcomes.
Upon completion of this activity, participants will be able to:
• Discuss the selection of antimicrobials considerate of their spectrum and impact on gut microbiota
• Evaluate the role of monoclonal antibodies in the treatment and prevention of recurrent C. difficile infection
• Describe clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Optimize diagnostic methods to improve recognition of C. difficile infection both in the hospital and community setting
• Discuss the selection of antimicrobials considerate of their spectrum and impact on gut microbiota
• Evaluate the role of monoclonal antibodies in the treatment and prevention of recurrent C. difficile infection
• Describe clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Optimize diagnostic methods to improve recognition of C. difficile infection both in the hospital and community setting
Supported by an educational grant from Merck & Co., Inc..
Lisa Ravindra, MD
Assistant Professor of Internal Medicine
Department of Internal Medicine
Rush University Medical Center
Chicago, IL
Assistant Professor of Internal Medicine
Department of Internal Medicine
Rush University Medical Center
Chicago, IL
Andrew Skinner, MD
Assistant Professor of Medicine
Department of Medicine/Division of Infectious Diseases
Loyola University Medical Center
Maywood, IL
Eugene Yen, MD
Gastroenterologist
Department of Medicine/Division of Internal Medicine
NorthShore University HealthSystem
Evanston, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Lisa Ravindra, MD (Faculty)
No financial relationships to disclose
Andrew Skinner, MD (Faculty)
Consultant: Recursion Pharmaceuticals
Eugene Yen, MD (Faculty)
Advisory Boards: Ferring Pharmaceuticals & Finch Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Fecal Microbiota Transplant (FMT)
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Ty Jackson at tjackson@achlcme.org.
ABIM credit will be submitted to ABIM on the first day of each month.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system.
